L O A D I N G
October 31, 2014

ORIC Pharmaceuticals Raises $15 Million Series A Financing

ORIC Pharmaceuticals, Inc. is a small molecule oncology company focused on combating the growing resistance problem to current molecularly targeted drugs. The Company raised $15.4 million in Series A financing with The Column Group II, LP as the major investor.

Founded in 2014 by world renowned cancer researchers, Drs. Charles Sawyers and Scott Lowe, from Memorial Sloan Kettering Cancer Center, the company is currently taking aim at clinical relapse in hormone-driven cancers such as prostate, with the aim or producing its first clinical candidate by early 2016. ORIC is also implementing a next generation screening platform to identify potential vulnerabilities in resistant tumors and reveal new targets for drug discovery.